Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v3-EN
Language English English
Date Updated 2021-03-11 2021-02-16
Drug Identification Number 02017741 02017741
Brand name RESONIUM CALCIUM RESONIUM CALCIUM
Common or Proper name Resonium Calcium Resonium Calcium
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients CALCIUM POLYSTYRENE SULFONATE CALCIUM POLYSTYRENE SULFONATE
Strength(s) 999MG 999MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration ORAL RECTAL ORAL RECTAL ORAL RECTAL ORAL RECTAL
Packaging size 1 1
ATC code V03AE V03AE
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2021-02-10 2021-02-10
Actual start date
Estimated end date 2021-04-09 2021-03-15
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Overselling - Shipping Delay The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Overselling - Shipping Delay The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments